Sera Prognostics Celebrates Illinois Legislation for Medicaid Coverage of Proteomic Testing in Pregnancy

Sera Prognostics Inc., recognized as The Pregnancy Company®, has expressed their support for recent legislative measures taken in Illinois that aim to broaden access to medical resources for pregnant individuals. This initiative specifically targets the integration of proteomic blood testing, an essential tool for early identification and management of risks related to preterm births. With over 250 premature births reported weekly in Illinois, this legislation comes as a timely intervention in the realm of maternal and neonatal health.

The recently amended Illinois Public Aid Code mandates that the state's Medicaid program will now cover prescribed proteomic blood tests that are instrumental in determining the likelihood of spontaneous preterm birth. Furthermore, the law instructs the provision and reimbursement of care management services, reinforcing the state's commitment to enhancing health outcomes for mothers and infants alike. The PreTRM® Test, developed by Sera Prognostics, stands out as the only validated blood-based test available on the market. Clinical evidence showcases its efficacy in predicting risks early, allowing for timely interventions.

The significance of this legislative initiative cannot be overstated, as preterm birth is a major contributor to maternal and neonatal complications across the country. The rising statistics—13,042 preterm births recorded in Illinois in 2024 alone—underscore the necessity for innovative and evidence-based approaches in this domain. Medicaid, which funds nearly half of all births nationwide, experiences significant financial and clinical strain caused by high rates of preterm births. By facilitating access to scientifically-driven tools, this new Illinois initiative sets a precedence for improving care management and health outcomes.

Zhenya Lindgardt, the President and CEO of Sera Prognostics, stated, “We are encouraged to see policymakers prioritizing innovative, evidence-based approaches to improving maternal health. Expanding access to proteomic testing represents an important step toward enabling earlier identification of risk and more personalized care for pregnant individuals.” Sera's proteomic testing methods are designed to deliver actionable insights about the risk of spontaneous preterm birth, thus aiding clinicians in making better-informed decisions regarding patient care.

As details of the Illinois initiative continue to unfold, Sera Prognostics is committed to assisting the implementation process and working with policymakers and other stakeholders to define coverage parameters. This collaborative approach highlights an essential strategy for improving health care access and affordability, marking a hopeful trajectory towards elevated maternal and neonatal health outcomes.

In addition to its focus on preterm birth risk assessment, Sera Prognostics develops a range of innovative diagnostic tests aimed at predicting complications that can arise during pregnancy. Their mission is to deliver critical insights that ultimately foster better care for women and their newborns, alleviating some of the economic burdens associated with these health challenges.

In conclusion, the legislative changes in Illinois signify a meaningful advancement in the approach to pregnancy care. The unfolding framework for Medicaid coverage of proteomic tests like the PreTRM® provides an encouraging outlook for the future of maternal health services, emphasizing the important role that public policy plays in supporting healthcare innovations.

By aligning emergency responses with data-driven decisions, such initiatives pave the way for improved outcomes not only for mothers and babies but also for healthcare programs at large. With ongoing support from both public and private sectors, the potential for positive change in maternal and neonatal health care remains bright.